Literature DB >> 18292519

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.

Laura Strauss1, Christoph Bergmann, Miroslaw J Szczepanski, Stephan Lang, John M Kirkwood, Theresa L Whiteside.   

Abstract

OBJECTIVE: Interaction of ICOS with its ligand (ICOSL, B7-H2) promotes T cell responses. As CD4+CD25highFoxp3+ naturally occurring T regulatory cells in melanoma patients express ICOS, we investigated the impact of ICOS on naturally occurring T regulatory cell function.
METHODS: Expression of ICOS and T regulatory (Treg) cell markers was determined on CD4+CD25high T cells in PBMC and tumor-infiltrating lymphocytes from melanoma patients (n=10) and PBMC of normal controls (n=10) by multicolor flow cytometry. Suppression mediated by sorted ICOShigh and ICOSlow Treg was assessed in CFSE-based suppression assays with autologous CD4+CD25- responder cells (RC). Transwell inserts separating Treg from RC were used to evaluate suppression mechanisms used by Treg. ICOShigh or ICOSlow Treg were coincubated with RC+/-TCR and IL-2 stimulation. ICOShigh and ICOS- Treg were also expanded under conditions previously shown to induce Tr1 from RC.
RESULTS: Treg in tumor-infiltrating lymphocytes expressed ICOS (mean fluorescence intensity=70+/-10), while Treg in PBMC had low ICOS expression (mean fluorescence intensity=3.5+/-2.5, p<or=0.001). ICOShigh Treg up-regulated Treg markers (p<or=0.0016) and mediated stronger suppression (p<or=0.001) relative to ICOSlow Treg. ICOShigh Treg induced Tr1 cells in nonactivated RC and Th2 cells in preactivated RC. ICOShigh Treg exposed to Tr1 cytokines expressed IL-10 and suppressed RC (92+/-12%) in contrast to ICOSlow Treg, which mediated low suppression (21+/-15%; p<or=0.0028).
CONCLUSION: ICOShigh Treg can induce diverse immune responses in RC, depending on activation signals and cytokines present. ICOShigh Treg induce Tr1 or Th2 cells depending on the activation state of RC. In a "Tr1" cytokine milieu, ICOShigh Treg transit to Tr1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292519     DOI: 10.4049/jimmunol.180.5.2967

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

2.  Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Authors:  Natalia Martin-Orozco; Yufeng Li; Yijun Wang; Shijuan Liu; Patrick Hwu; Yong-Jun Liu; Chen Dong; Laszlo Radvanyi
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells.

Authors:  Erika Cretney; Annie Xin; Wei Shi; Martina Minnich; Frederick Masson; Maria Miasari; Gabrielle T Belz; Gordon K Smyth; Meinrad Busslinger; Stephen L Nutt; Axel Kallies
Journal:  Nat Immunol       Date:  2011-03-06       Impact factor: 25.606

Review 4.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

Review 5.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

6.  Upregulation of SCC-S2 in immune cells and tumor tissues of papillary thyroid carcinoma.

Authors:  Dong Duan; Yu-Quan Zhu; Li-Li Guan; Jie Wang
Journal:  Tumour Biol       Date:  2014-01-24

7.  The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Authors:  Kritika Kachapati; David E Adams; Yuehong Wu; Charles A Steward; Daniel B Rainbow; Linda S Wicker; Robert S Mittler; William M Ridgway
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

8.  Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.

Authors:  Michal Kuczma; Magdalena Kopij; Iwona Pawlikowska; Cong-Yi Wang; Grzegorz A Rempala; Piotr Kraj
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

9.  IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Authors:  Geok Choo Sim; Natalia Martin-Orozco; Lei Jin; Yan Yang; Sheng Wu; Edwina Washington; Deborah Sanders; Carol Lacey; Yijun Wang; Luis Vence; Patrick Hwu; Laszlo Radvanyi
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

10.  Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta.

Authors:  Anja Scholzen; Diana Mittag; Stephen J Rogerson; Brian M Cooke; Magdalena Plebanski
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.